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ABSTRACT
HRAS is a frequently mutated oncogene in cancer. However, mutant HRAS 
as drug target has not been investigated so far. Here, we show that mutant HRAS 
hyperactivates the RAS and the mTOR pathway in various cancer cell lines including 
lung, bladder and esophageal cancer. HRAS mutation sensitized toward growth 
inhibition by the MEK inhibitors AZD6244, MEK162 and PD0325901. Further, we found 
that MEK inhibitors induce apoptosis in mutant HRAS cell lines but not in cell lines 
lacking RAS mutations. In addition, knockdown of HRAS by siRNA blocked cell growth 
in mutant HRAS cell lines. Inhibition of the PI3K pathway alone or in combination 
with MEK inhibitors did not alter signaling nor had an impact on viability. However, 
inhibition of mTOR or combined inhibition of MEK and mTOR reduced cell growth in a 
synergistic manner. Finally, Ba/F3 cells transformed with mutant HRAS isoforms Q61L, 
Q61R and G12V demonstrated equal sensitivity towards MEK and mTOR inhibition. 
Our results show that HRAS mutations in cancer activate the RAS and mTOR pathways 
which might serve as a therapeutic option for patients with HRAS mutant tumors.
INTRODUCTION
Harvey-RAS (HRAS) belongs to the RAS family 
of small GTPases which activate the RAS–RAF–MEK–
ERK pathway. Mutations in RAS family members lead to 
hyperactivity of the RAS signaling pathway. HRAS is a 
frequently mutated oncogene especially in head and neck 
cancer (3.9%), bladder cancer (5.1%), vulvar squamous 
cell carcinoma (9.3%), cutaneous squamous cell carcinoma 
and lung cancer (3.8%) [1–3]. This adds up to a significant 
number of patients eligible for putative targeted therapies. 
Frequency of HRAS mutations varies. Histological 
subtypes could play a role as a report described a high 
frequency of HRAS mutations in inverted urothelial 
papilloma (IUP) - an uncommon neoplasm of the urinary 
bladder with distinct morphologic features [4]. In addition, 
HRAS mutations seem to be more frequent in squamous 
cell cancer of the lung (2.8%) than in adenocarcinoma of 
the lung (1%) [2, 5]. Clinical characteristics and behavior 
of HRAS mutant cancer patients have been described 
scarcely. One recent report described an adenocarcinoma 
of the lung with HRAS Q61L mutation suffering from 
rapid progression and deterioration suggesting that HRAS 
mutations in NSCLC tumors might be aggressive and 
associated with poor overall prognosis, similar to KRAS 
mutant NSCL [6]. Interestingly, one phase I trial for the 
novel Mitogen-activated protein kinase kinase (MEK) 
inhibitor RO5126766 reported a tumor patient with HRAS 
mutation that showed 20% tumor shrinkage due to MEK 
inhibitor treatment [7]. This is the first hint that HRAS 
mutant cancer patients might benefit clinically from MEK 
inhibitor treatment. However, whether HRAS mutations 
generally sensitize towards treatment with MEK inhibitors 
has not been investigated yet. Further, little is known about 
signaling of oncogenic HRAS and putative druggability. 
Typical hotspots for HRAS mutations are found at 
codon 12, 13 and 61, resulting in G12C/S, G13R/V and 
Q61R/L mutations [8]. These positions for mutations 
of HRAS are at the very same sides as mutations found 
for NRAS [9]. As of today, mutant NRAS has been far 
better investigated, mainly in melanoma but also in other 
cancers such as lung cancer and T-cell lymphoma. NRAS 
mutations are mostly found at codon 61 and to a fewer 
extend at codons 12 and 13. NRAS mutations occur at 
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about 15% to 25% in melanoma patients [10, 11] and are 
known to activate the RAS–RAF–MEK–ERK pathway. 
Approaches targeting oncogenic NRAS directly including 
farnesylation inhibitors have failed. But inhibiting 
downstream MEK kinase by MEK kinase inhibitors 
was proven to be successful in melanoma, lung cancer 
and T-cell lymphoma cell lines [12–14]. MEK inhibitors 
blocked cell growth at clinical relevant concentrations 
and even induced apoptosis [12–14]. Mutant NRAS 
was also shown to activate the PI3K/mechanistic target 
of rapamycin (mTOR)-signaling cascade and combined 
inhibition of MEK and PI3K was synergistic in certain 
NRAS mutant cell lines of melanoma, lung cancer and 
neuroblastoma [14, 15]. More important, the concept of 
targeted treatment of NRAS mutant melanoma could be 
demonstrated within clinical trials. In a phase II trial 30 
patients with NRAS mutant melanoma were treated with 
the MEK inhibitor MEK162. 20% of treated patients 
showed a partial response and 43% stable disease [16]. 
These promising results will be further studied in a phase 
III clinical trial [17].
In the present study, we investigated HRAS 
downstream signaling in five different cancer cell lines 
including lung and bladder cancer and putative drugs for 
targeted therapy. We observed that lung cancer cell lines 
harboring HRAS mutations showed significant higher 
sensitivity to MEK inhibitors than HRAS wild-type cell 
lines. Further, the effect of MEK inhibitors was enhanced 
synergistically by the addition of mTOR but not PI3K 
inhibitors. Inhibition of mTOR alone is sufficient to block 
cell growth in HRAS mutant but not wild-type cell lines. 
To our knowledge, we describe for the first time that 
HRAS mutations can be targeted by MEK and mTOR 
inhibitors.
RESULTS
MEK inhibitors block cell growth in HRAS 
mutant cancer cell lines
In order to study HRAS mutations we collected 
HRAS mutant cancer cell lines including KNS-62, 
NCI-H1915, T24, RL95–2 and KYSE-30 (Figure 1A). 
Sequencing data for primary tumor tissue available 
at COSMIC data base revealed that the HRAS Q61L 
mutation is the most common in lung cancer of 
adenocarcinoma and squamous cell cancer (Figure 1B). 
This is reflected by the two lung cancer cell lines KNS-62 
(squamous) and NCI-H1915 (adenocarcinoma) which both 
harbor a Q61L mutation. The HRAS G12V mutation is 
predominant in bladder cancer which was detected in the 
T24 bladder cancer cell line (Figure 1B) [19]. HCC827 
is a cell line with described EGFR mutation and HCC78 
was found to harbor a ROS1 translocation [20, 21]. RAS 
kinases are well known to activate the RAS–RAF–MEK–
ERK cascade and several MEK inhibitors are under 
clinical development including AZD6244 (Selumetinib) 
and MEK162 (Binimetinib) [16, 22]. This prompted us 
to ask whether MEK inhibitors could be of relevance 
for treatment of HRAS mutated patients. We detected 
that HRAS mutant cell lines KNS-62, NCI-H1915, T24, 
RL95–2 and KYSE-30 had significantly lower EC50 
values for MEK inhibition than HRAS wild-type cells such 
as CAL12T, HCC44, HCC827 and HCC78 (Figure 1C,1D, 
Supplementary Figure S1A). EC50 value for HRAS wild 
type cell lines CAL12T was 2.15 μM and for HCC44, 
HCC827 or HCC78 EC50 was above 3 μM (Figure 1C). 
In contrast, HRAS mutant cell lines had EC50 values for 
AZD6244 ranging from 4–5nM (T24 and RL95–2) over 
166–258nM (KNS-62, NCI-H1915) to 437nM (KYSE-30) 
(Figure 1C). EC50 values for MEK162 were found 
to be in a similar range (Figure 1D). These are clinical 
relevant plasma concentrations since maximal plasma 
concentrations of AZD6244 and MEK162 are at 1.75 
μM and 1.13 μM, respectively [23, 24]. Next, we wanted 
to investigate efficacy of MEK inhibitors under serum-
reduced and hypoxic conditions. Though cell growth 
was slightly impaired under serum-reduced conditions 
MEK inhibitors efficiently blocked cell growth in HRAS 
mutant cell lines (Supplementary Figure S1B). Under 
hypoxic conditions with 0.2% oxygen cell growth of 
controls was strongly impaired (data not shown) and, thus, 
MEK inhibitors were slightly less efficient than under 
standard cell culture conditions (Supplementary Figure 
S1B). Further, we checked whether inhibition of MEK 
blocks signaling of the RAS–RAF–MEK–ERK pathway. 
AZD6244, MEK162 and PD0325901 blocked basal ERK 
phosphorylation in all HRAS mutant cell lines (Figure 1E). 
ERK phosphorylation was not blocked in HRAS wild-type 
cell lines (Supplementary Figure S1C). Taken together this 
data shows, that HRAS mutation results in hyperactivation 
of the RAS pathway in cancer cell lines from various 
tissues and that this activation sensitizes towards treatment 
with MEK inhibitors.
Mutant HRAS is critical for survival of mutant 
HRAS cancer cell lines
Since MEK inhibitors block cell growth we wanted 
to analyze whether induction of apoptosis occurs in 
HRAS mutant cancer cell lines. We incubated cell lines 
with MEK inhibitors and measured apoptosis 72 hours 
later. Indeed, MEK inhibitor MEK162 induced apoptosis 
in HRAS mutant cell lines KNS-62, NCI-H1915, T24, 
RL95–2 and KYSE-30 but not in HRAS wild-type cell 
lines (Figure 2A, 2B). Apoptosis measured ranged between 
18% and 60% for HRAS mutant cell lines (Figure 2C). 
To further study the role of HRAS, we performed a 
specific HRAS knockdown by 2 different siRNAs. HRAS 
siRNA reduced protein expression of HRAS which 
subsequently resulted in significantly reduced cell growth 
of HRAS mutant cell lines compared to wild-type cell 
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Figure 1: MEK inhibition blocks cell growth in HRAS mutant cells. A. Presentation of HRAS mutant and HRAS wild-type cell 
lines. Mutations were detected by PCR of cDNA covering the open reading frame of HRAS and confirmed mutation status from COSMIC 
data base. PCR products were purified and sent for sequencing. B. Distribution of HRAS mutations from tumor tissue of lung (upper 
panel) and bladder (lower panel) available from COSMIC data base. C, D. Mutant HRAS und wild-type HRAS cell lines were treated 
with 6 increasing concentrations of AZD6244 and MEK162 for 96 hours. Then, cell growth was measured by Cell Titer Glo according to 
the manufacturer’s instructions. EC50 values were calculated with GraphPad Prism and depicted at bars. Statistical significance between 
mutant and wild-type cell lines was calculated with student’s t-test. E. All cell lines were kept under equal conditions, then treated with 
500nM of AZD6244, MEK162 and PD0325901 for 1 hour and next lysed and subjected to Western blot. Phosphorylation levels of ERK 
and MEK were detected by specific anti-phospho antibodies. Loading was verified by specific antibodies to total ERK, MEK and anti–actin.
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Figure 2: MEK inhibitors induce apoptosis in HRAS mutant cell lines. A. HRAS mutant cell lines were incubated with 
indicated concentrations of MEK inhibitors MEK162 for 72 hours. Then, apoptosis was determined by Annexin V and PI staining. B. 
Same as A. but HRAS wild-type cell lines were used instead. C. Quantification of apoptosis by AnnexinV / PI assay. Specific apoptosis 
was calculated for all cell lines as described in M&M section. D. Accell siRNA against HRAS (siHRAS1 and siHRAS2) were transfected 
in HRAS mutant and HRAS wild-type cell lines according to manufacturer’s instructions. 96 hours after transfection, cells were lysed 
and lysates subjected to Western blot. Efficiency of knockdown was measured by anti-HRAS antibodies. Equal loading was controlled by 
antiactin antibodies. Cell growth was also assessed after 96 h by Cell titer Glo. Statistical significance between mutant and wild-type cell 
lines was calculated with student’s t-test.
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lines (Figure 2D). These results show that HRAS mutant 
cell lines are addicted to continuous HRAS activity which 
is required for survival.
Combined inhibition of MEK and mTOR 
synergistically reduces cell growth in HRAS 
mutant tumor cells
Previously, it was demonstrated that mutant NRAS 
melanoma cells are sensitive to the combination of MEK 
and PI3K inhibitors [14]. We found that the NCI-H1915 
cell line had no detectable phosphorylation levels of 
AKT Ser 473 despite strong expression of basal AKT 
(Figure 3A). Further, pan-PI3K inhibitor BKM120 did 
not alter phosphorylation of AKT Ser 473 in KNS-62 cell 
line (Figure 3A). These findings are in line with a lack 
of growth inhibition for single pan-PI3K inhibition or 
combined treatment with MEK162 in HRAS mutant cell 
lines (Figure 3B). These results were further supported 
by studies with a second PI3K kinase inhibitor BYL719 
which had no effect on cell growth (data not shown). 
We conclude that inhibition of the PI3K pathway is not 
relevant for survival and cell growth of HRAS mutant 
cancer cells.
Enhanced apoptosis and tumor growth suppression 
by combination of MEK and mTOR inhibitors was 
previously observed in HRAS wild-type lung cancer 
cell lines [25]. Therefore, we asked the question whether 
inhibition of the down-stream mTOR complex could 
be an effective target for mutant HRAS. The clinically 
available mTOR inhibitor Everolimus blocked activity of 
S6, a kinase downstream of mTOR, in HRAS mutant cell 
lines (Figure 4A). This inhibition of the mTOR pathway 
translated in blockage of cell growth preferentially in 
HRAS mutant cancer cell lines (Figure 4A). Encouraged 
by these results, we aimed to investigate the combination 
of mTOR inhibitor Everolimus and MEK inhibitors. If 
used together, combination of Everolimus and AZD6244/
MEK162 caused a stronger inhibition of S6 kinase than 
single use of Everolimus on Western blot (Figure 4B; 
Supplementary Figure S2A). The combination of 
Everolimus and AZD6244 / MEK162 also translated in 
a stronger blockade of cell growth in HRAS mutant cells 
than single use (Figure 4C; Supplementary Figure S2B). 
Of note, concentrations used for combined inhibition 
are at very low nanomolar concentrations for both 
Everolimus and AZD6244 or MEK162 (Figure 4C; 
Supplementary Figure S2B). More important, the 
combination of Everolimus and MEK inhibitors was 
found to be synergistic according to method of Chou-
Talalay [18]. Synergism is defined by a combination 
index (CI) inferior 1 [18]. MEK162 showed stronger 
synergism with Everolimus than AZD6244 (Figure 4C). 
To further support the synergistic action of mTOR and 
MEK inhibitors in HRAS mutant cells we used the 
novel mTOR1/2 inhibitor AKT8055 which entered 
early clinical trials [26]. AKT8055 blocked downstream 
phosphorylation of S6 kinase alone (Figure 4B). Yet, 
phosphorylation of S6 kinase was further blocked if 
AKT8055 was used in combination with MEK inhibitors 
(Figure 4B). Combination of AKT8055 and MEK 
inhibitors also blocked cell growth synergistically in 
mutant HRAS cell lines according to Chou-Talalay 
(Figure 4D; Supplementary Figure S2C). To summarize, 
these data show that combination of mTOR and MEK 
inhibitors synergistically inhibit downstream signaling and 
cell growth of HRAS mutant cell lines.
Mutant HRAS-driven transformation of Ba/F3 
cells is sensitive to MEK inhibitors
We wanted to study the functional consequences of 
the different HRAS mutations including Q61L, Q61R and 
G12V in more detail by testing their abilities to transform 
interleukin-3 (IL-3)-dependent murine lymphoid Ba/
F3 cells to cytokine-independent growth. Removal of 
IL-3 lead to a clear difference in cell proliferation. Ba/
F3 cells expressing ectopic HRAS Q61L, Q61R or 
G12V mutations showed strong cell growth whereas 
Ba/F3 cells with wild-type HRAS or empty vector 
stopped cell growth (Supplementary Figure S3A). Ba/
F3 cells expressing mutant versions of HRAS exhibited 
constitutive phosphorylation of ERK and S6 which was 
blocked by MEK162 or Everolimus, respectively (Figure 
5A, 5B). All mutant HRAS forms including Q61L, Q61R 
and G12V sensitized equally towards MEK inhibitor or 
mTOR inhibitor treatment compared to control vector 
cell line kept under IL-3 (Figure 5C, 5D). The calculated 
EC50 values of transformed Ba/F3 cells were at low 
nanomolar range as observed for mutant cell lines. Since 
combined treatment of MEK and mTOR inhibitor resulted 
in stronger suppression of S6 phosphorylation than 
treatment with single inhibitors (Figure 5B), we wanted 
to check combined treatment on cell growth. In both 
HRAS mutants, Q61L and G12V, combination of MEK 
and mTOR inhibition caused a synergistic blockade of cell 
growth (Figure 5E, 5F). To conclude, these data clearly 
show that the different HRAS mutations at Q61 and G12 
confer equal sensitivity towards inhibition of downstream 
MEK and mTOR pathway (Figure 5G).
Combined inhibition of MEK and mTOR 
synergistically blocks tumor growth in-vivo
Next, we wanted to evaluate efficacy of MEK and 
mTOR inhibitors in a murine xenograft model. We tested 
several cell lines and found the human lung cancer cell line 
KNS-62 most suitable for xenotransplantation. Treatment 
of animals with oral AZD6244 or Everolimus resulted in a 
significant reduction in tumor growth in-vivo (Figure 6A). 
In addition, combination of AZD6244 and Everolimus 
even further reduced tumor growth in-vivo (Figure 6A). 
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Of note, combination treatment was significantly more 
effective than single treatment for both agents (Figure 6A). 
These results were supported by determination of tumor 
weight at the end of the xenotransplantation. Again, 
tumor weight was significantly reduced in AZD6244 and 
Everolimus treated animals (Figure 6B) and tumor weight 
was significantly lower in the combination treatment arm 
(Figure 6B). We conclude that single and combination 
treatment of AZD6244 and Everolimus block tumor 
growth in-vivo.
Figure 3: Inhibition of PI3K pathway does not influence signaling or cell growth. A. KNS-62 and NCI-H1915 cells were 
treated with 500nM of AZD6244, MEK162 and BKM120 or combinations thereof as indicated for 1 h. Then, cells were lysed and analysed 
by Western blot. B. KNS-62, NCI-H1915, T24 and RL95–2 cells were left untreated or treated with indicated concentrations of MEK162 
and BKM120 for 96 hours. Next, cell growth was measured by Cell Titer Glo according to the manufacturer’s instructions. CIs are indicated.
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Figure 4: Inhibition of the mTOR pathway blocks cell growth in HRAS mutant cell lines. A. HRAS mutant and wild-type 
cells were left untreated or treated with indicated concentrations of Everolimus for 96 hours. Next, cell growth was measured by Cell Titer 
Glo according to the manufacturer’s instructions (left panel). In addition, all HRAS mutant cell lines were treated with 10nM Everolimus 
for 1 hour. Then, cells were lysed and analysed by Western blot applying phospho-S6 antibody and anti-actin antibodies for loading control 
(right panel). B. KNS-62 and T24 cells were treated with 250nM AZD6244, 250nM MEK162, 5nM of Everolimus, 250nM AKT8055 or 
combinations thereof as indicated for 1 hour. Then, cells were lysed and analysed by Western blot. CIs are indicated. C. KNS-62 and T24 
cells were left untreated or treated with indicated concentrations of Everolimus and AZD6244/MEK162 for 96 hours. Then, cell growth 
was measured by Cell Titer Glo according to the manufacturer’s instructions. CIs are indicated. D. Same as in C., but the mTOR inhibitor 
AZD8055 was used instead of Everolimus. CIs are indicated.
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Figure 5: HRAS mutants transform Ba/F3 cells which become sensitive to MEK and mTOR inhibition. A. Ba/F3 cells 
or Ba/F3 cells transduced with empty vector were kept under 0,1 ng/ml IL-3. Ba/F3 cells transduced with HRAS Q61L, Q61R or G12V 
grew independent of IL-3 and were kept under puromycin selection with 1ug/ml. Cells were lysed and analysed by Western blot with 
indicated antibodies. B. Ba/F3 clones were kept under same conditions as described in A. Cells were treated with 250nM AZD6244, 5nM 
of Everolimus or combinations thereof as indicated for 1 hour. Then, cells were lysed and analyzed by Western blot. C. Ba/F3 clones were 
kept under same conditions as described in A. Ba/F3 cells transduced with empty vector or HRAS Q61L, Q61R or G12V were treated with 
increasing concentrations of MEK162. Then, cell growth was measured by Cell Titer Glo after 96 h. D. Same as in C., but Everolimus was 
used instead. E, F. HRAS Q61L or G12V expressing clones were left untreated or treated with indicated concentrations of Everolimus and 
MEK162 for 96 hours. Then, cell growth was measured by Cell Titer Glo. CIs are indicated. G. Schematic  representation of mutant HRAS 
signaling pathways. Mutant HRAS can be blocked by inhibition of downstream MEK and mTOR but not by PI3K.
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DISCUSSION
Lung adenocarcinomas have mutually exclusive 
mutations in receptor tyrosine kinase (RTK) and RAS 
pathway oncogenes such as EGFR and KRAS [1]. Further 
oncogenic mutations can be found in HRAS, NRAS, 
BRAF, ERBB2, MET, MAP2K1 and RIT1 [1, 27]. 
Targeting ‘driver’ mutations including EGFR in lung 
cancer and BRAF in melanoma resulted in great clinical 
success [28, 29]. Whereas targeting mutant KRAS 
remained difficult, several studies demonstrated that 
NRAS mutations can be targeted by inhibition of MEK 
in tumor cell lines [12, 13, 15]. Inhibition of MEK in 
NRAS mutant melanoma was also successful in a phase 
II trial and a large phase III trial is planned [16, 17]. In 
this study we were able to show for the first time that 
HRAS mutant cancer cell lines can be targeted by MEK 
kinase inhibition (Figure 1). Interestingly, the effect 
of susceptibility towards MEK inhibition could be 
observed for different background of cancer types. HRAS 
mutation conferred MEK sensitivity in lung cancer of 
adenocarcinoma and squamous origin, bladder cancer, 
endometrium cancer and squamous esophageal cancer cell 
lines (Figure 1). This is in accordance with mutations of 
Figure 6: AZD6244 and Everolimus block tumor growth in-vivo as single agents and in combination. A. HRAS mutant 
lung cancer cell line KNS-62 xenografts were treated with AZD6244 (20 mg/kg), or Everolimus 3.5 mg/kg), or a combination of AZD6244 
and Everolimus (20 mg/kg and 3.5mg/kg, respectively), or vehicle (DMSO). Each group consisted of 5 mice and tumor volumes (mm3) are 
shown. Error bars represent standard error values and significance is (* = p < 0.05; ** = p < 0.01). B. Xenografts were explanted at the end 
of experiments and tumor weight was measured. Significance is (* = p < 0.05; ** = p < 0.01; *** = p < 0.001).
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NRAS that sensitize towards MEK inhibitors in different 
kind of tissues including lung cancer, neuroblastoma, 
melanoma and T-cell lymphoma [12, 13, 15]. HRAS and 
NRAS seem to share signaling similarities which cause 
also similar sensitivity towards targeted treatment. Both, 
HRAS and NRAS mutations activate the RAS and the 
mTOR pathway and induce sensitivity towards MEK 
inhibitors. All HRAS mutations studied here are at typical 
known sites for activating mutations including G12V and 
Q61L. We found that HRAS mutations at position G12 
or Q61 rendered transformed Ba/F3 equally sensitive 
to MEK inhibitors indicating that all activing mutations 
at position G12 and Q61 might be eligible for targeted 
treatment patients with HRAS mutant tumors (Figure 1, 4). 
Other mutations outside this hotspots at position 12, 13 
and 61 do occur but are rare (Figure 1, (COSMIC, 2015)). 
It is not clear whether HRAS mutations outside these 
hotspots are non-functional passenger mutations or rare 
activating mutations which have been identified e.g. for 
N- and KRAS in leukemia [30]. HRAS mutations are 
frequent with about 2.8 – 5.1% in lung and bladder cancer, 
however, rather infrequent in endometrium and esophageal 
cancer with about 1% each [31]. Yet our data indicates 
that, though rare, patients with HRAS mutated tumors 
of different tumor histology might benefit from targeted 
therapy. This was further promoted by experiments 
in which MEK inhibitors do not only cause growth 
inhibition but also induced apoptosis in HRAS mutant 
cancer cells (Figure 2). Targeting oncogenic HRAS by 
specific kinase inhibitors might be also relevant for tumors 
associated with so-called RASophathies. HRAS as proto-
oncogene was associated with Costollo syndrome – a 
congenital disorder characterized by coarse face, loose 
skin, cardiomyopathy and predisposition to tumors such 
as benign papillomas or malign rhabdomyosarcomas, 
neuroblastoma and bladder cancer [32]. Patients, but not 
parents, showed mutations of HRAS at position glycine 12 
and 13 [32]. However, targeting HRAS might be limited 
by development of resistance as seen for BRAF inhibitors 
in melanoma [33, 34].
To overcome possible resistance mechanisms 
and to expand the list of possible drugs we investigated 
combinations of PI3K or mTOR inhibitors with MEK 
inhibitors. For NRAS mutant cancers the combination 
of MEK and the dual PI3K/mTOR were described to 
be synergistic [14, 35, 36]. However, we found that 
inhibition of PI3K with the inhibitor BKM120 alone or in 
combination did not block cell growth or further enhanced 
it (Figure 3). The PI3K inhibitor BYL719 did not work 
synergistically either (data not shown). Our observations 
are supported by recent clinical data. The combination of 
BKM120 with MEK inhibitor Trametinib failed to achieve 
a reasonable response in RAS- or BRAF-mutant lung 
cancer patients in a phase Ib trial [37]. We speculated if 
mutant HRAS might signal to the mTOR complex directly 
without involving PI3K/AKT. This is reflected by our 
observations showing that the mTOR inhibitor Everolimus 
alone was sufficient to block cell growth in HRAS 
mutant cells compared to wild-type cell lines (Figure 
4, 5). However, HRAS mutations seem to be a better 
predictive marker for MEK sensitivity compared to mTOR 
sensitivity. The effect of mTOR inhibitors on HRAS 
mutant cells was altogether less pronounced compared 
to MEK inhibitors. The effect of mTOR inhibitors was 
also minor compared to MEK inhibitors in NRAS mutant 
melanoma cells [14]. Yet, the combination of both drugs 
was synergistic and this synergism occurred at very 
low nanomolar concentrations which are also relevant 
for clinical treatment and might be associated with less 
toxicity (Figure 4, 5). Since most kinase inhibitors are in 
early clinical development, only some studies investigated 
combination thereof. One recent report demonstrated 
that the combination of AZD6244 and the AKT inhibitor 
MK2206 is tolerable in a phase I trial [38].
HRAS mutation status was barely tested within 
clinical trials. Early clinical trials investigating Everolimus 
in non-small cell lung cancer (NSCLC) showed partial 
responses (PR) for some patients, however, mutation 
status was not determined [39, 40]. A very recent trial 
testing AZD6244 in a KRAS/NRAS/HRAS mutant cohort 
reported one PR out of 10 patients included; however, the 
mutation status of these 10 specific patients treated with 
AZD6244 was not indicated [41].
We have shown that mutant HRAS is a potential 
drug target in different types of cancer including lung 
cancer and bladder cancer. HRAS mutations sensitize to 
single treatment with MEK and mTOR inhibitors which 
can be further enhanced by combinations of MEK and 
mTOR inhibitors. Thus, our data may encourage clinical 
studies on HRAS mutant cancer patients.
MATERIALS AND METHODS
Chemicals
Murine IL-3 was purchased from Sigma-Aldrich. 
AZD6244, MEK162 and PD0325901 were purchased 
from Selleck Chemical. Everolimus and AZD8055 were 
purchased from MedChemExpress. All inhibitors were 
solubilized in dimethyl sulfoxide (DMSO) at stock 
concentrations of 1 mM.
Cell culture
T24 and KNS62 were purchased from National 
Institute of Biomedical lnnovation JCRB Cell Bank, 
Japan. NCI-H1915, Phoenix and RL952 were purchased 
from ATCC. KYSE-30, CAL-12T, HCC44, HCC78 and 
Ba/F3 were purchased from DSMZ (Deutsche Sammlung 
von Mikroorganismen und Zellkulturen), Germany. Lung 
cancer cell line NCI-H1915 cells were cultured in RPMI 
medium supplemented with 10% fetal calf serum (FCS) 
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and 1 mM L-glutamine. KNS62, T24 and CAL12T cells 
were cultured in DMEM medium supplemented with 10% 
fetal calf serum and 1 mM L-glutamine. RL952 cells were 
cultured in DMEM and F12 medium (1:1) supplemented 
with 10% fetal calf serum, 0.005 mg/ml insulin (1:100 
Opi) and 1 mM L-glutamine. KYSE30 cells were cultured 
in RPMI 1640 and F12 medium (1:1) supplemented with 
10% fetal calf serum and 1 mM L-glutamine. Lung cancer 
cell lines HCC44 and HCC78 cells were cultured in RPMI 
medium supplemented with 10% fetal calf serum and 1 
mM L-glutamine. Lung cancer cell line HCC827 cells 
were cultured in RPMI medium supplemented with 20% 
fetal calf serum and 1 mM L-glutamine. Ba/F3 cells were 
maintained in RPMI-1640 supplemented with 10% FCS 
and 0.5 ng/ml murine IL-3 (Sigma-Aldrich). For serum 
reduced experiments cell lines were kept in Accell serum 
free media (Dharmacon) supplemented with 1% FCS. For 
hypoxia studies cells were kept for 96 h in a 0.2% hypoxia 
chamber Invivo2 400 (Ruskinn).
siRNA transfection and knockdown
KNS-62, NCI-H1915, T24, RL95–2, KYSE-30, 
CAL12T, HCC44, HCC827, and HCC78 were transfected 
with either control or two different siRNAs against HRAS. 
Accell siRNA was purchased from Dharmacon and used 
according to the manufacturer’s protocol. In brief, siRNAs 
were diluted in Accell siRNA Delivery Media from 
Dharmacon to a final concentration of 1uM. Knock-down 
efficiency was observed after 96 h.
Ba/F3 assays
Ba/F3 cells were transduced retrovirally with empty 
pMSCV-Puro (kindly provided by Dr. Balabanov) or 
pMSCV-Puro expression wild-type HRAS, HRAS Q61L, 
HRAS Q61R, HRAS G12V with the help of 293T Phoenix 
cells (ATCC). Synthesis of HRAS or HRAS mutants, 
cloning and DNA sequencing of cloned inserts was 
performed by LifeTechnologies. Transduced cells were 
seeded at concentrations below 1 × 106/ml, selected with 
puromycin at 1 μg/ml (in addition with 0.1 ng/ml IL-3) 
3d after transduction. Section pressure was maintained 
for at least 1 week, then IL-3 was reduced under ongoing 
puromycin treatment. IL-3 independent clones grew out 
after 5–7 days and were kept under puromycin 1 μg/ml.
Western blot analysis
A total of 0.5 × 106 cells were lysed for 30 minutes 
in ice-cold MPERM buffer supplemented with 25 mM 
NaF, 1 mM dithiothreitol, and complete protease inhibitor 
cocktail from Roche Diagnostics. Cell debris was 
removed by centrifugation at 10000 rpm for 10 minutes, 
loading buffer added and treated for 5 min at 95°C. Then, 
proteins were separated by gel electrophoresis. Separated 
proteins were blotted onto a nitrocellulose membrane 
(GE Healthcare) which was blocked with 5% bovine 
serum albumin in phosphate-buffered saline/Tween 
(0.05% Tween-20 in phosphate-buffered saline). The 
following antibodies were used: anti-phospho-ERK 
(P-p44/p42 (Tyr202/204, #9101, Cell Signaling 
Technology), anti-ERK (p44/p42, # 4695, Cell Signaling 
Technology), anti-phospho Akt (Ser473, # 4085, Cell 
Signaling Technology), anti-panAKT (# 9272, Cell 
Signaling Technology), anti-phospho MEK (Ser298, 
#9128, Cell Signaling Technology), anti-MEK (# 8727, 
Cell Signaling Technology), anti-phospho mTOR 
(Ser2448, #2971, Cell Signaling Technology),anti-mTOR 
(# 2972, Cell Signaling Technology), anti-HRAS rabbit (# 
ab97488, Abcam) and anti–actin (Sigma-Aldrich).
PCR and sequencing of cell lines
Isolation of cellular RNA was done by using the 
Qiagen RNA Purification Kit (Qiagen). RNA (1 μg) was 
reverse transcribed into cDNA with a reverse transcription-
PCR kit (Applied Biosystems). Next, 5 μL of cDNA was 
taken for a PCR of 50 μL volume. We used the following 
primers: HRAS forward, 5_-ggggcaggagaccctgtag-3_; 
HRAS reverse. PCR was performed, and 30 μL of 
PCR product was sent for sequencing to Microsynth, 
Switzerland. For sequencing, we used the same primers as 
for the PCR. Mutations can be found in Cancer Cell Line 
Encyclopedia (Encyclopedia, 2015).
Apoptosis assays
Cell lines were treated with indicated concentrations 
of inhibitors and apoptosis was measured after 48 h 
and 72 h. Apoptosis was assessed by AnnexinV–APC 
(Enzo Lifescience) and propidium iodide (PI) (Sigma-
Aldrich) by FACS. Both reagents were diluted to a final 
concentration of 1.5%. Specific cell death was calculated 
by the following equation: specific cell death % = (% 
experimental cell death - % spontaneous cell death)/(100% 
- % spontaneous cell death) x 100 (Jin et al., 2006).
Cell proliferation and viability assays
Cell proliferation was determined by Cell-Titer-
Glo Reagent (Promega) according to the manufacturer’s 
instructions. Cells were plated in 96-well plates at a 
density of 500 - 2500 cells per well. The next day, 
drugs were added at indicated concentrations and cell 
proliferation was measured 4 days later. Measurement of 
proliferation was done using a 96-well plate luminometer/
plate reader (Synergy 2, Biotek). Data were calculated 
as relative values: luminescence for a given drug 
concentration was compared to luminescence of untreated 
cells. All experimental points were set up in duplicate 
replicates and were conducted at least 3 independent 
times. IC50 were calculated with GraphPad Prims. 
Combination index (CI) values with CalcuSyn Software 
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(Biosoft) according to Chou-Talalay [18]. CI values less 
than one were considered synergistic.
Mouse xenotransplantation
We tested lung cancer cell line KNS-62 and bladder 
cancer cell line T24 for engraftment rates by subcutaneous 
injection in CB17 SCID-/- mice. Engraftment and growth 
rate was excellent for KNS-62 already after 6 days but 
poor for T24 cells (tumors shrinked after 14d). Finally, 
we xenotransplanted 1*106 KNS-62 cells into CB17 
SCID-/- mice. Engrafted tumors reached 150 mm3 after 6 
days and animals were randomized into 4 groups: DMSO 
only (n = 5), AZD6244 (Selumetinib) at 20mg/kg (n = 5), 
Everolimus at 3.5mg/kg (n = 5), and combined AZD6244 
and Everolimus at 20mg/kg and 3.5mg/kg respectively 
(n = 5). Inhibitors were kept at stock concentrations of 
250 mM (AZD6244) and 10 mM (Everolimus), diluted in 
1000ul DMSO each and carefully diluted in animal water. 
Concentrations were adjusted to 4ml drink volume per day 
which was the observed volume for previous experiments. 
Tumor size and weight was monitored three times 
weekly, and the mouse technician who was measuring 
tumor size was blinded to grouping until the trial was 
completed. Determination of tumor volume was done by 
3 dimensional digital caliper measurements. Statistical 
analysis of the experiment was done by a two-tailed t 
test at each time point. P-values < 0.05 (*), or p-values 
< 0.01 (**) were considered significant between different 
treatment groups. The animal study was performed in 
accordance with the University Zurich Animal Committee 
and animals were euthanized as soon as tumor volume 
exceeded 3000 mm3 or necrosis of tumors.
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